Related Experiment Videos
Are predictive biomarkers of toxicity worth having? An economic model
Byron Jones1, Dennis A Smith, Esther F Schmid
1Sandwich Laboratories, Pfizer Global Research and Development, Sandwich, Kent, UK.
Abstract:
In this paper we model the cost-benefit of excluding populations at risk through predictive toxicity biomarkers and diagnostics. False positives/ negatives inherent in predictive markers and the frequency and nature of adverse events determine whether biomarkers are beneficial and economically viable. We present a model that takes these and other factors into account using data largely in line with real world cases.
Related Concept Videos
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Toxicity Testing in Animals
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacodynamic Models: Overview
Mutagenicity and Carcinogenicity